Acquired by Halozyme Therapeutics in May 2022
ATRS - Antares Pharma, Inc.
NASDAQ
->
Healthcare
->
Medical Instruments & Supplies
Ewing,
United States
Type: Equity
ATRS price evolution
ATRS
| (in millions $) | 31 Mar 2022 | 31 Dec 2021 | 30 Oct 2021 | 30 Jun 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $61.72 | $65.91 | $57.37 | $45.13 |
| Short term investments | $0.5 | $1.25 | ||
| Net receivables | $84.14 | $83.01 | $54.47 | $54.22 |
| Inventory | $11.59 | $11.54 | $16.49 | $18.64 |
| Total current assets | $171.59 | $174.27 | $133.43 | $127.96 |
| Long term investments | ||||
| Property, plant & equipment | $30.23 | $29.79 | $25.83 | $29.6 |
| Goodwill & intangible assets | $18.79 | $18.97 | $7.07 | $7.28 |
| Total noncurrent assets | $84.07 | $83.23 | $83.31 | $84.66 |
| Total investments | $0.5 | $1.25 | ||
| Total assets | $255.66 | $257.5 | $216.74 | $212.62 |
| Current liabilities | ||||
| Accounts payable | $19.88 | $17.06 | $12.88 | $15.8 |
| Deferred revenue | $4.31 | $4.43 | $3.8 | $2.67 |
| Short long term debt | $2.54 | $2.4 | $3.83 | $23.85 |
| Total current liabilities | $55.73 | $58.93 | $52.53 | $71.97 |
| Long term debt | $22.95 | $22.82 | $18.4 | $7.89 |
| Total noncurrent liabilities | $24.16 | $22.82 | $23.38 | $8.62 |
| Total debt | $25.49 | $25.22 | $26.85 | $31.74 |
| Total liabilities | $79.89 | $81.75 | $75.91 | $80.59 |
| Shareholders' equity | ||||
| Retained earnings | -$178.66 | -$176.34 | -$209.02 | -$214.41 |
| Other shareholder equity | -$0.69 | -$0.69 | -$0.69 | -$0.69 |
| Total shareholder equity | $175.77 | $175.76 | $140.83 | $132.03 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $65.91 | $53.14 | $23.2 | $27.89 |
| Short term investments | $1.25 | $22.52 | ||
| Net receivables | $83.01 | $42.22 | $35.07 | $18.98 |
| Inventory | $11.54 | $18.22 | $16 | $11.35 |
| Total current assets | $174.27 | $126.59 | $108.45 | $71.31 |
| Long term investments | ||||
| Property, plant & equipment | $29.79 | $28.64 | $21.42 | $14.89 |
| Goodwill & intangible assets | $18.97 | $8.79 | $1.57 | $1.93 |
| Total noncurrent assets | $83.23 | $85.94 | $24.3 | $16.97 |
| Total investments | $1.25 | $22.52 | ||
| Total assets | $257.5 | $212.53 | $132.75 | $88.28 |
| Current liabilities | ||||
| Accounts payable | $17.06 | $16.19 | $12.9 | $11.13 |
| Deferred revenue | $4.43 | $3.94 | $1.74 | $1.02 |
| Short long term debt | $2.4 | $17.43 | $1.25 | $3.04 |
| Total current liabilities | $58.93 | $63.2 | $32.41 | $27.19 |
| Long term debt | $22.82 | $29.48 | $45.84 | $22.08 |
| Total noncurrent liabilities | $22.82 | $30.21 | $45.84 | $22.08 |
| Total debt | $25.22 | $46.92 | $47.09 | $25.13 |
| Total liabilities | $81.75 | $93.42 | $78.25 | $49.28 |
| Shareholders' equity | ||||
| Retained earnings | -$176.34 | -$222.63 | -$278.83 | -$276.8 |
| Other shareholder equity | -$0.69 | -$0.68 | -$0.7 | -$0.7 |
| Total shareholder equity | $175.76 | $119.11 | $54.5 | $39 |
| (in millions $) | 31 Mar 2022 | 31 Dec 2021 | 30 Oct 2021 | 30 Jun 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $41.56 | $48.73 | $48.19 | $44.98 |
| Cost of revenue | $15.65 | $16.25 | $11.63 | |
| Gross Profit | $25.91 | $32.48 | $31.76 | $33.35 |
| Operating activities | ||||
| Research & development | $5.01 | $3.89 | $4.05 | |
| Selling, general & administrative | $20.6 | $18.67 | $17.7 | |
| Total operating expenses | $25.61 | -$16.03 | $24.23 | $21.75 |
| Operating income | $0.3 | $48.51 | $7.96 | $11.6 |
| Income from continuing operations | ||||
| EBIT | -$2.96 | $45.87 | $6.7 | |
| Income tax expense | -$0.82 | $12.42 | $1.83 | $1.14 |
| Interest expense | $0.17 | $0.76 | $0.75 | $1.14 |
| Net income | ||||
| Net income | -$2.32 | $32.68 | $5.39 | $4.42 |
| Income (for common shares) | -$2.32 | $32.68 | $4.42 | |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $183.98 | $149.6 | $123.86 | $63.55 |
| Cost of revenue | $54.42 | $53.96 | $50.48 | $31.07 |
| Gross Profit | $129.56 | $95.64 | $73.39 | $32.49 |
| Operating activities | ||||
| Research & development | $14.5 | $10.12 | $10.62 | $12.33 |
| Selling, general & administrative | $73.86 | $62.76 | $61.77 | $36.76 |
| Total operating expenses | $49.77 | $72.88 | $72.4 | $36.59 |
| Operating income | $79.8 | $22.76 | $0.99 | -$4.1 |
| Income from continuing operations | ||||
| EBIT | $65.88 | $13.71 | $1.52 | -$3.84 |
| Income tax expense | $15.98 | -$46.28 | ||
| Interest expense | $3.61 | $3.79 | $3.55 | $2.67 |
| Net income | ||||
| Net income | $46.29 | $56.2 | -$2.03 | -$6.51 |
| Income (for common shares) | $46.29 | $56.2 | -$2.03 | -$6.51 |
| (in millions $) | 31 Mar 2022 | 31 Dec 2021 | 30 Oct 2021 | 30 Jun 2021 |
|---|---|---|---|---|
| Net income | -$2.32 | $32.68 | $13.61 | $4.42 |
| Operating activities | ||||
| Depreciation | $0.93 | $1.14 | $0.92 | |
| Business acquisitions & disposals | -$13.81 | |||
| Stock-based compensation | $1.94 | $2.17 | $2.06 | |
| Total cash flows from operations | -$4.88 | $9.49 | $27.13 | $6.43 |
| Investing activities | ||||
| Capital expenditures | -$0.08 | $16.17 | -$1.27 | |
| Investments | $0.75 | -$1.25 | ||
| Total cash flows from investing | $0.67 | $1.11 | -$4.96 | -$1.27 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.91 | $0.08 | $0.54 | |
| Net borrowings | -$0.38 | -$1.85 | -$15 | |
| Total cash flows from financing | $0.02 | -$2.05 | -$17.94 | -$15.69 |
| Effect of exchange rate | -$0 | -$0 | ||
| Change in cash and equivalents | -$4.2 | $8.55 | $4.23 | -$10.53 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Net income | $46.29 | $56.2 | -$2.03 | -$6.51 |
| Operating activities | ||||
| Depreciation | $3.9 | $2.63 | $2.56 | $2.72 |
| Business acquisitions & disposals | -$13.81 | |||
| Stock-based compensation | $8.02 | $7.95 | $6.47 | $4.93 |
| Total cash flows from operations | $36.62 | $21.32 | -$10.62 | -$17.32 |
| Investing activities | ||||
| Capital expenditures | $11.21 | -$9.33 | $2.65 | $6.65 |
| Investments | -$1.25 | $22.5 | -$22.64 | $5 |
| Total cash flows from investing | -$3.85 | $8.17 | -$20 | $11.61 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $5.18 | $1.81 | $12.19 | $7.59 |
| Net borrowings | -$22.05 | $14.86 | ||
| Total cash flows from financing | -$19.99 | $0.45 | $25.92 | $7.04 |
| Effect of exchange rate | -$0 | $0 | $0 | |
| Change in cash and equivalents | $12.78 | $29.94 | -$4.69 | $1.33 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $183.46M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $40.17M |
| Revenue Q/Q | -1.25% |
| Revenue Y/Y | 15.67% |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | 17.05% |
| ROE | 25.74% |
| Debt/Equity | 0.47 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.08 |
| Quick ratio | 2.87 |